These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 16618755

  • 1. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L, Zhang N, Leal J, Bush TL, Santora V, Askew B, Tasker A, Radinsky R, Kendall R, Coats S.
    Cancer Res; 2006 Apr 15; 66(8):4299-308. PubMed ID: 16618755
    [Abstract] [Full Text] [Related]

  • 2. Mitogen requirement for cell cycle progression in the absence of pocket protein activity.
    Foijer F, Wolthuis RM, Doodeman V, Medema RH, te Riele H.
    Cancer Cell; 2005 Dec 15; 8(6):455-66. PubMed ID: 16338659
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
    Gregory CW, Johnson RT, Presnell SC, Mohler JL, French FS.
    J Androl; 2001 Dec 15; 22(4):537-48. PubMed ID: 11451350
    [Abstract] [Full Text] [Related]

  • 4. Phospholipase C delta 1 regulates cell proliferation and cell-cycle progression from G1- to S-phase by control of cyclin E-CDK2 activity.
    Kaproth-Joslin KA, Li X, Reks SE, Kelley GG.
    Biochem J; 2008 Nov 01; 415(3):439-48. PubMed ID: 18588506
    [Abstract] [Full Text] [Related]

  • 5. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45.
    Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ.
    Oncogene; 1999 May 06; 18(18):2892-900. PubMed ID: 10362260
    [Abstract] [Full Text] [Related]

  • 6. New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.
    Higginbottom K, Jahnke U, Newland AC, Cotter FE, Allen PD.
    Apoptosis; 2007 Oct 06; 12(10):1847-55. PubMed ID: 17636382
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [Abstract] [Full Text] [Related]

  • 8. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
    Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.
    Cancer Res; 2005 Oct 01; 65(19):9038-46. PubMed ID: 16204078
    [Abstract] [Full Text] [Related]

  • 9. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L.
    Radiother Oncol; 2006 Aug 01; 80(2):185-91. PubMed ID: 16905211
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms underlying the pro-survival pathway of p53 in suppressing mitotic death induced by adriamycin.
    Lin YC, Wang FF.
    Cell Signal; 2008 Jan 01; 20(1):258-67. PubMed ID: 18006273
    [Abstract] [Full Text] [Related]

  • 11. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.
    Thomas HD, Wang LZ, Roche C, Bentley J, Cheng Y, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR.
    Eur J Cancer; 2011 Sep 01; 47(13):2052-9. PubMed ID: 21570822
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of cell-cycle progression in HeLa cells by HY52, a novel cyclin-dependent kinase inhibitor isolated from Bauhinia forficata.
    Lim H, Kim MK, Lim Y, Cho YH, Lee CH.
    Cancer Lett; 2006 Feb 20; 233(1):89-97. PubMed ID: 16473670
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle.
    Lin CC, Lin SY, Chung JG, Lin JP, Chen GW, Kao ST.
    Anticancer Res; 2006 Feb 20; 26(2A):1097-104. PubMed ID: 16619512
    [Abstract] [Full Text] [Related]

  • 14. G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein.
    Gonzales AJ, Fry DW.
    Exp Cell Res; 2005 Feb 01; 303(1):56-67. PubMed ID: 15572027
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P, Davis B, Law M, Chytil A, Forrester E, Nørgaard P, Teoh N, Law B.
    Cancer Res; 2007 Apr 01; 67(7):3135-44. PubMed ID: 17409420
    [Abstract] [Full Text] [Related]

  • 19. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
    Chang HL, Wu YC, Su JH, Yeh YT, Yuan SS.
    J Pharmacol Exp Ther; 2008 Jun 01; 325(3):841-9. PubMed ID: 18337475
    [Abstract] [Full Text] [Related]

  • 20. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo.
    Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL, Harn HJ.
    Clin Cancer Res; 2005 May 01; 11(9):3475-84. PubMed ID: 15867250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.